AN2 Therapeutics, Inc.
ANTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $40 | $55 | $30 | $17 |
| G&A Expenses | $14 | $15 | $13 | $5 |
| SG&A Expenses | $14 | $15 | $13 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $55 | $70 | $42 | $22 |
| Operating Income | -$55 | -$70 | -$42 | -$22 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $5 | $1 | $0 |
| Pre-Tax Income | -$51 | -$65 | -$41 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$65 | -$41 | -$22 |
| % Margin | – | – | – | – |
| EPS | -1.72 | -2.74 | -2.79 | -1.5 |
| % Growth | 37.2% | 1.8% | -86% | – |
| EPS Diluted | -1.72 | -2.74 | -2.79 | -1.5 |
| Weighted Avg Shares Out | 30 | 24 | 15 | 19 |
| Weighted Avg Shares Out Dil | 30 | 24 | 15 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $55 | $70 | $0 | $0 |
| EBITDA | $3 | $5 | -$41 | -$22 |
| % Margin | – | – | – | – |